Other studies have synthesized exosome-liposome hybrid nanovesicles to modulate microglial dysfunction and Aβ anabolism, thus rescuing the cognitive function of the APP/PS1 mouse model (Jiang et al., 2024), suggesting the potential clinical applications of these exosome-related nanovesicles for AD treatment. Here, APP is linked to Alzheimer disease.